natgillin/translations-raw huggingface dataset:
Compound according to Claim 1, in which R1 represents an -OR5, - O-Alk-OR5, -COOR5 or -O-Alk-COOR5 group or a phenyl group optionally substituted with one or more alkyl or -COOR5 groups, in which R5 represents a hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms, and Alk represents an alkylene chain containing 1 or 2 carbon atoms, or a heteroaryl group, preferably a pyridinyl group. 
Spoj prema zahtjevu 1, naznačen time da R1 predstavlja -OR5, - O-Alk-OR5, -COOR5 ili -O-Alk-COOR5 skupinu ili fenilnu skupinu proizvoljno supstituiranu s jednom ili više alkil ili -COOR5 skupina, gdje R5 predstavlja vodikov atom ili alkil skupinu koja sadrži od 1 do 4 ugljikova atoma, i Alk predstavlja alkilenski lanac koji sadrži 1 ili 2 ugljikova atoma, ili heteroarilnu skupinu, poželjno piridinil skupinu.
Compounds according to Claim 1 or 2, in which R1 represents an -OR5, -O-Alk-OR5 or -O-Alk-COOR5 group or a phenyl group optionally substituted with one or more alkyl or -COOR5 groups, in which R5 represents a hydrogen atom or a methyl group, and Alk represents an alkylene chain containing 1 or 2 carbon atoms, or a heteroaryl group, preferably a pyridinyl group. 
Spojevi prema zahtjevu 1 ili 2, naznačeni time da R1 predstavlja -OR5, -O-Alk-OR5 ili -O-Alk-COOR5 skupinu ili fenilnu skupinu proizvoljno supstituiranu s jednom ili više alkil ili -COOR5 skupina, gdje R5 predstavlja vodikov atom ili metil skupina, i Alk predstavlja alkilenski lanac koji sadrži 1 ili 2 ugljikova atoma, ili heteroarilnu skupinu, poželjno piridinil skupinu.
Compounds of formula (I) according to Claims 1 to 3, in which R2 represents an alkyl group containing from 1 to 4 carbon atoms or a phenyl group. 
Spojevi s formulom (I) prema zahtjevima 1 do 3, naznačeni time da R2 predstavlja alkilnu skupinu koja sadrži od 1 do 4 ugljikova atoma ili fenilnu skupinu.
Rc" represents a hydrogen atom or an alkyl or alkenyl group, . 
RC" predstavlja vodikov atom ili alkilnu ili alkenil skupinu, .
said alkyl or alkenyl groups mentioned above contain from 1 to 4 carbon atoms, 
gore navedene alkilne ili alkenilne skupine sadrže od 1 do 4 ugljikova atoma, .
. R7 and R8 represent hydrogen atoms or alkyl groups containing from 1 to 4 carbon atoms, or together form a 5- or 6-membered saturated ring, 
R7 i R8 predstavljaju vodikove atome ili alkil skupine koje sadrže od 1 do 4 ugljikova atoma, ili tvore zajedno 5- ili 6-člani zasićeni prsten, .
. Alk' represents a linear, branched, cyclic or partially cyclic alkylene chain containing from 1 to 4 carbon atoms. 
Alk' predstavlja linearni, razgranati, ciklički ili djelomično ciklički alkilenski lanac koji sadrži od 1 do 4 ugljikova atoma.
Compounds of formula (I) according to Claim 5, in which R3 and R4 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to either of formulae (A) and (C), the radicals Ra, Ra', Rc, Rc' and Rc" being as defined in Claim 1. 
Spojevi s formulom (I) prema zahtjevu 5, naznačeni time da R3 i R4 tvore zajedno, s ugljikovim atomima fenilne jezgre na koju su spojeni, 6-člani dušikov heterocikal koji odgovara bilo kojoj od formula (A) i (C), a radikali Ra, Ra', Rc, Rc' i Rc" su kako je definirano u zahtjevu 1.
Compound of formula (I) according to Claim 5, in which R3 and R4 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to formula (C), Rc, Rc' and Rc" being as defined in Claim 1. 
Spoj s formulom (I) prema zahtjevu 5, naznačen time da R3 i R4 tvore zajedno, s ugljikovim atomima fenilne jezgre na koju su spojeni, 6-člani dušikov heterocikal koji odgovara formuli (C), te su Rc, Rc' i Rc" kako je definirano u zahtjevu 1.
Process for preparing the compounds of formula (I) according to any one of Claims 1 to 7 in which R3 and R4 together form, with the carbon atoms of the phenyl nucleus to which they are attached, a 6-membered nitrogenous heterocycle corresponding to formula (A), R1 represents an -OR5, -O-Alk-OR5, -COOR5, -O-Alk-COOR5, -O-Alk-OR5, O-Alk-NR5R6 or -O-Alk-NR7R8 group, and R2 is as defined in Claim 1, characterized in that: 
Postupak za pripremanje spojeva s formulom (I) prema bilo kojem od zahtjeva 1 do 7 u kojima R3 i R4 tvore zajedno, s ugljikovim atomima fenilne jezgre na koju su spojeni, 6-člani dušikov heterocikal koji odgovara formuli (A), R1 predstavlja -OR5, -O-Alk-OR5, -COOR5, -O-Alk-COOR5, -O-Alk-OR5, O-Alk-NR5R6 ili -O-Alk-NR7R8 skupinu, i R2 je kako je definirano u zahtjevu 1, naznačen time da:
the compound of formula (IV) is subjected to a basic hydrolysis reaction in order to obtain the compound of formula (V): 
spoj s formulom (IV) se podvrgava bazičnoj reakciji hidrolize kako bi se dobio spoj s formulom (V): [image]
an esterification of the compound of formula (V) is carried out and the compound of formula (VI) is obtained: 
provodi se esterifikacija spoja s formulom (V) i dobiven je spoj s formulom (VI): [image]
the compound of formula (VI) is subjected to the action of triphosgene so as to form the isocyanate corresponding to the compound of formula (VI), and then this isocyanate is condensed with an amine of formula RaNH2, Ra being as defined in Claim 1, in order to obtain the urea of formula (VII), 
spoj s formulom (VI) se podvrgava djelovanju trifosgena tako da se stvori izocijanat koji odgovara spoju s formulom (VI), te se zatim ovaj izocijanat kondenzira sa aminom s formulom RaNH2, te je Ra kako je definirano u zahtjevu 1, kako bi se dobila urea s formulom (VII), [image]
the compound of formula (X) is subjected to a basic hydrolysis reaction in order to obtain the compound of formula (XI): 
spoj s formulom (X) se podvrgava bazičnoj reakciji hidrolize kako bi se dobio spoj s formulom (XI): [image]
an esterification of the compound of formula (XI) is carried out and the compound of formula (XII) is obtained: 
provodi se esterifikacija spoja s formulom (XI) i dobiven je spoj s formulom (XII): [image]
the compound of formula (XII) is reached with N-bromosuccinimide and the compound of formula (XIII) is obtained: 
spoj s formulom (XII) je dobiven s N-bromosukcinimidom i dobiven je spoj s formulom (XIII): [image]
the compound (XXI) is subjected to an alkylation reaction in the presence of a base and of a halogenated derivative Rc"X, Rc" being as defined in Claim 1 and X being a halogen, or of a protective group, and the compound of formula (XXII) is obtained: 
spoj (XXI) se podvrgava reakciji alkilacije u prisutnosti baze i halogeniranog derivata Rc"X, te je Rc" kako je definirano u zahtjevu 1 i X je halogen, ili zaštitnoj skupini, te je dobiven spoj s formulom (XXII): [image]
the compound (XXII) is subjected to a condensation reaction with a malonic derivative in order to obtain the compound of formula (XXIII): in which Rc' and Rc are defined in Claim 1, 
spoj (XXII) se podvrgava reakciji kondenzacije s derivatom malonske kiseline kako bi se dobio spoj s formulom (XXIII): [image] u kojoj su Rc' i Rc definirani u zahtjevu 1,
the compound of formula (XXIII) is subjected to a deprotection reaction. 
spoj s formulom (XXIII) se podvrgava reakciji deprotekcije.
the compound of formula (XII) is reacted with N-bromosuccinimide and the compound of formula (XIII) is obtained: 
spoj s formulom (XII) reagira sa N-bromosukcinimidom i dobiven je spoj s formulom (XIII): [image]
the compound (XVIII) is subjected to a condensation reaction in order to obtain the compound (XXIV): 
spoj (XVIII) se podvrgava reakciji kondenzacije kako bi se dobio spoj (XXIV): [image]
the compound of formula (XXIV) is subjected to an alkylation reaction in the presence of a base and of a halogenated derivative Rc"X, Rc" being as defined in Claim 1 and X being a halogen, or of a protective group, in order to obtain the compound of formula (XXV): 
spoj s formulom (XXIV) se podvrgava reakciji alkilacije u prisutnosti baze i halogeniranog derivata RC"X, te je RC" kako je definirano u zahtjevu 1 i X je halogen, ili zaštitne skupine, kako bi se dobio spoj s formulom (XXV): [image]
the compound of formula (XXV) is subjected to a condensation reaction with a malonic derivative in order to obtain the compound of formula (XXVI): in which Rc' and Rc are as defined in Claim 1, 
spoj s formulom (XXV) se podvrgava reakciji kondenzacije s derivatom malonske kiseline kako bi se dobio spoj s formulom (XXVI): [image] u kojoj su RC' i RC kako je definirano u zahtjevu 1,
the compound of formula (XXVI) is subjected, in the presence of a palladium catalyst, of a ligand and of a base, to a reaction with phenylboronic or heteroarylboronic or phenylboronate ester or heteroarylboronate ester derivatives according to a Suzuki coupling, in order to obtain the compound of formula (XXVII): 
spoj s formulom (XXVI) se podvrgava, u prisutnosti paladijevog katalizatora, liganda i baze, reakciji sa fenilboratnim ili heteroarilboratnim ili fenilboronatnim esterom ili derivatima heteroarilboronatnog estera u skladu sa Suzuki spajanjem, kako bi se dobio spoj s formulom (XXVII): [image]
the compound of formula (XXVII) is subjected to a deprotection reaction. 
spoj s formulom (XXVII) se podvrgava reakciji deprotekcije.
the compound of formula (XXVIII) is subjected to a reaction in the presence of iron and of acetic acid and the compound of formula (XXIX) is obtained: 
spoj s formulom (XXVIII) se podvrgava reakciji u prisutnosti željeza i octene kiseline i dobiven je spoj s formulom (XXIX): [image]
the compound of formula (XXIX) is subjected to a condensation reduction and the compound of formula (XXX) is obtained: 
spoj s formulom (XXIX) se podvrgava kondenzacijskoj redukciji i dobiven je spoj s formulom (XXX): [image]
Compound according to any one of Claims 1 to 8, for use thereof in the treatment and prevention of cancers, in particular carcinomas which have a high degree of vascularization, such as lung, breast, prostate, pancreatic, colon, kidney and oesophageal carcinomas, cancers which induce metastases, such as colon cancer, liver cancer and stomach cancer, melanomas, gliomas, lymphomas, leukaemias, and also thrombopenias. 
Spoj prema bilo kojem od zahtjeva 1 do 8, naznačen time da je za primjenu za liječenje i sprječavanje karcinoma, naročito karcinoma koji imaju visok stupanj vaskularizacije, kao što su rak pluća, rak dojke, rak prostate, rak gušterače, rak debelog crijeva, rak bubrega i ezofagealni karcinomi, te karcinomi koji induciraju metastaze, kao što su rak debelog crijeva, rak jetre i rak želuca, melanomi, gliomi, limfomi, leukemije, te također trombopenije.
An aminopyridine selected from the following group: 
Aminopiridin odabran iz grupe koju čine:
An aminopyridine for use according to claim 15 wherein the co-agent is selected from artemether, chloroquine, mefloquine, quinine, atovaquone/proguanil, doxycycline, artesunate, hydroxychloroquine, halofantrine, pyrimethamine-sulfadoxine, primaquine and piperaquine. 
Aminopiridin za upotrebu prema patentnom zahtjevu 15, naznačen time da je ko-agens odabran iz grupe koju čine artemeter, klorokin, meflokin, kinin, atovakvon/progvanil, doksiciklin, artesunat, hidroksiklorokin, halofantrin, pirimetamin-sulfadoksin, primakin i piperakin.
A compound, pharmacologically acceptable ester thereof, or pharmacologically acceptable salt thereof according to any one of claims 13 to 15, wherein, in the case where R7 represents a group having a hydroxy group (a hydroxy C1-C6 alkyl group, a hydroxyhalo C1-C6 alkyl group, a hydroxy C1-C6 alkoxy group, a hydroxy C1-C6 alkylcarbamoyl group, or a hydroxy C1-C6 alkylcarbamoyl C1-C6 alkyl group), the hydroxy group forms an ester bond with a C1-C6 alkanoyl group. 
Spoj, njegov farmakološki prihvatljiv ester ili njegova farmakološki prihvatljiva sol prema bilo kojem od patentnih zahtjeva 13 do 15, gdje, u slučaju gdje R7 predstavlja grupu koja ima hidroksi grupu (hidroksi C1-C6 alkil grupu, hidroksihalo C1-C6 alkil grupu, hidroksi C1-C6 alkoksi grupu, hidroksi C1-C6 alkilkarbamoil grupu ili hidroksi C1-C6 alkilkarbamoil C1-C6 alkil grupu), hidroksi grupa formira estersku vezu sa C1-C6 alkanoil grupom.
A pharmaceutical composition for use according to claim 20, wherein the anemia is anemia incidental to chronic kidney disease. 
Farmaceutska kompozicija za uporabu prema patentnom zahtjevu 20, gdje je anemija – anemija koja se javlja kod kronične bolesti bubrega.
A compound, pharmacologically acceptable ester thereof, or pharmacologically acceptable salt thereof for use according to claim 25, wherein the anemia is anemia incidental to chronic kidney disease. 
Spoj, njegov farmakološki prihvatljiv ester ili njegova farmakološki prihvatljiva sol za uporabu prema patentnom zahtjevu 25, gdje je anemija – anemija koja se javlja kod kronične bolesti bubrega.
it is arranged at a horizontal distance to a surface area (10o) of the ladle bottom used as an impact area (10i) for a metal melt poured onto said ladle bottom, 
raspoređena je na horizontalnom razmaku od površinskog područja (10o) dna grabilice, koje se upotrebljava kao područje udara (10i) za rastopljenu metalnu masu ulivenu na spomenuto dno grabilice,
it defines a secondary upper surface (10od) of the ladle bottom, vertically below the upper surface (10u), 
određuje sekundarnu gornju površinu (10od) dna grabilice, koja se nalazi vertikalno ispod gornje površine (10o),
the pouring channel (16) runs through said diffusor box (DB) and indentation (IN) 
uljevni kanal (16) protječe kroz spomenutu difuznu kutiju (DB) i udubljenje (IN).
Ladle bottom according to claim 1 or 2, wherein at least one of the following surfaces of the ladle bottom has a three dimensional profile: upper surface (10o), secondary upper surface (10od), tertiary upper surface (10oi), quaternary upper surface (10or). 
Dno grabilice prema zahtjevu 1 ili 2, naznačeno time, da najmanje jedna od sljedećih površina od dna grabilice, ima trodimenzionalni profil: gornja površina (10o), sekundarna gornja površina (10od), tercijarna gornja površina (10oi), kvaternarna gornja površina (10or).
Ladle bottom according to claim 1 or 2, wherein at least one of the following surfaces of the ladle bottom has a polygonal, circular or oval shape: secondary upper surface (10od), tertiary upper surface (10oi), quaternary upper surface (10or). 
Dno grabilice prema zahtjevu 1 ili 2, naznačeno time, da najmanje jedna od sljedećih površina od dna grabilice, ima poligonalni, kružni ili ovalni oblik: sekundarna gornja površina (10od), tercijarna gornja površina (10oi), kvaternama gornja površina (10or).
Ladle bottom according to claim 1, wherein adjacent upper surfaces (10o, 10od, 10oi, 10or) of the ladle bottom are dimensioned such that the upper surface (10or, 10oi, 10od) being closer to the lower surface (10u) of the ladle bottom, has an overall area being <60% of the surface (10oi, 10od, 10o) arranged on top. 
Dno grabilice prema zahtjevu 1, naznačeno time, da su susjedne gornje površine (10o, 10od, 10oi, 10or) od dna grabilice, tako dimenzionirane, da gornja površina (10or, 10oi, 10od) koja je bliža donjoj površini (10u) od dna grabilice, ima zauzeto ukupno područje koje je
Ladle bottom according to claim 1 or 2, wherein adjacent upper surfaces (10o, 10od; 10od, 10oi; 10oi, 10or) of the ladle bottom are vertically offset by 20 to 200mm, thereby forming a step (S) at least about part of their respective peripheries. 
Dno grabilice prema zahtjevu 1 ili 2, naznačeno time, da su susjedne gornje površine (10o, 10od; 10od, 10oi; 10oi, 10or) od dna grabilice, vertikalno razmaknute s 20 do 200 mm, čime se oblikuje stuba (S) barem oko dijela svojih odgovarajućih oboda.
Ladle bottom according to claim 8, wherein the step (S) extends along at least 50% of the periphery of the lower of said upper surfaces (10od, 10oi, 10or) 
Dno grabilice prema zahtjevu 8, naznačeno time, da se stuba (S) proteže uzduž najmanje 50% od oboda donje od navedenih gornjih površina (10od, 10oi, 10or).
Ladle bottom according to claim 1 or 2, wherein the diffusor box (DB) describes a horizontal area which corresponds to 3,7 to 32,9% of the total upper surface area (10o) of the ladle bottom. 
Dno grabilice prema zahtjevu 1 ili 2, naznačeno time, da difuzna kutija (DB) određuje horizontalno područje koje odgovara za 3,7 do 32,9% od ukupnog područja gornjih površina (10o) dna grabilice.
X is a phenyl or heteroaryl ring substituted with A, wherein A is at least one member selected from the group of -H, -halo, -hydroxyl, -C1-6 alkyl, -C1-6 alkoxy, and -COOR2; 
X je fenil ili heteroaril prsten supstituiran sa A, gdje je A najmanje jedan član izabran iz grupe koju čine -H, -halo, -hidroksil, -C1-6 alkil, -C1-6 alkoksi i -COOR2;
can also be selected from the group of: 
također može biti izabran iz grupe koju čine:
or R4 and R5 are taken together with the adjacent N to form a cycle such as 
ili R4 i R5 su uzeti zajedno sa susjednim N tako da formiraju ciklus kao što je [image] ili [image]
and R7 are independently selected from the group of -H, -C1-6 alkyl, -C1-6 substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, and -C1-6 alkyl-Q1, or R6 and R7 are taken together with the adjacent N to form a cycle selected from the group of Rc = C1-6 alkyl, NR2R2, -COOR3; 
i R7 su nezavisno izabrani iz grupe koju čine -H, -C1-6 alkil, -C1-6 supstituiran alkil, aril, heteroaril, supstituiran aril, supstituiran heteroaril i -C1-6 alkil-Q1, ili R6 i R7 su uzeti zajedno sa susjednim N tako da formiraju ciklus izabran iz grupe koju čine [image] [image] [image] i [image] RC = C1-6 alkil, NR2R2, -COOR3;
or R11 and R12 are taken together with the adjacent N to form a cycle selected from the group of and 
ili R11 i R12 su uzeti zajedno sa susjednim N tako da formiraju ciklus izabran iz grupe koju čine [image] i [image] i
and R15 are independently selected from the group of -H,-C1-6 alkyl, and -C1-6 alkylsubstituted alkyl, or R14 and R15 are taken together with the adjacent N to form a cycle selected from the group of 
i R15 su nezavisno izabrani iz grupe koju čine -H,-C1-6 alkil i -C1-6 alkil supstituiran alkil, ili R14 i R15 su uzeti zajedno sa susjednim N tako da formiraju ciklus izabran iz grupe koju čine [image] i [image]
A compound of claim 1 which is selected from the group consisting of: and 
Spoj prema patentnom zahtjevu 1 koji je izabran iz grupe koja se sastoji od:
The pharmaceutical composition of claim 12, useful for treating infection by HIV, which additionally comprises an antiviral effective amount of an AIDS treatment agent selected from the group consisting of: 
Farmaceutska kompozicija prema patentnom zahtjevu 12, korisna za liječenje HIV infekcije, koja dodatno sadrži antivirusno efikasnu količinu sredstva za liječenje SIDA-e izabranog iz grupe koja se sastoji od:
another HIV entry inhibitor. 
drugog inhibitora ulaska HIV-a.
A compound as claimed in any one of claims 1 to 11 for use in a method for treating a mammal infected with the HIV virus. 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 11 za uporabu u postupku za liječenje sisavca inficiranog HIV virusom.
An intermediate compound which is selected from the group of: wherein R3 is as defined in claim 1 
Intermedijerni spoj koji je izabran iz grupe od: [image] gdje je R3 kao što je definiran u patentnom zahtjevu 1.
Pharmaceutical or nutritional composition according to claim 1 for use in the prevention and /or treatment of gastroesophageal reflux disease. 
Farmaceutski ili nutritivni sastav prema patentnom zahtjevu 1 za uporabu u prevenciji i/ili liječenju bolesti gastroezofagijalnog refluksa.
maintaining the cell under conditions sufficient to express a fully human antibody; and 
održavanje stanice u uvjetima koji su dovoljni za eksprimiranje potpuno humanog protutijela i
is selected from the series consisting of hydrogen and (C1-C4)-alkyl; is selected from the series consisting of hydrogen, (C1-C4)-alkyl and (C3-C7)-cycloalkyl; 
je odabran iz niza kojeg čine vodik i (C1-C4)-alkil; je odabran iz niza kojeg čine vodik, (C1-C4)-alkil i (C3-C7)-cikloalkil;
a replacement at the endogenous mouse k immunoglobulin light chain variable region locus of all endogenous mouse k immunoglobulin light chain variable region gene segments with a rearranged human Vk1-39/J gene segment, a rearranged human Vk3-20/J gene segment, or a combination thereof, wherein the human gene segment is operably linked to an endogenous mouse k constant gene and wherein the mouse lacks an endogenous mouse k immunoglobulin light chain variable region locus that is capable of rearranging and forming a gene that encodes a mouse k variable region; and, 
zamjenu genskih segmenata varijabilne regije lakog lanca endogenog mišjeg k imunoglobulina na lokusu varijabilne regije lakog lanca endogenog mišjeg k imunoglobulina s jednostrukim preuređenim humanim genskim segmentom Vk1-39/Jk ili jednostrukim preuređenim humanim genskim segmentom Vk3-20/Jk, pri čemu je humani genski segment operativno povezan na endogeni mišji konstantni gen k i pri čemu mišu nedostaje lokus lakog lanca endogenog mišjeg k imunoglobulina koji je sposoban preurediti i formirati gen koji kodira mišju k varijabilnu regiju i
the mouse further comprising a mouse k intronic enhancer 5' with respect to the mouse light chain constant region; or 
miš dodatno sadržava mišji k pojačivač introna 5' u odnosu na konstantnu regiju mišjeg lakog lanca ili
the mouse further comprises a mouse k 3' enhancer. 
miš dodatno sadrži mišji pojačivač k 3'.
A fusion protein comprising 
Fuzijski protein koji obuhvaća
The fusion protein of claim 1, wherein upon exposure to a ligand of the ligand binding domain of a nuclear hormone receptor, the fusion protein is capable of inducing apoptosis in a cell, preferably a eukaryotic cell, expressing the fusion protein. 
Fuzijski protein prema zahtjevu 1, gdje nakon što se ligand izloži domeni koja kao ligand veže nuklearni hormonski receptor, fuzijski protein može inducirati apoptozu u stanici, poželjno eukariotskoj stanici, koja eksprimira fuzijski protein; i/ili
The fusion protein of claim 3, wherein the Caspase is a mammalian Caspase, especially a murine or human Caspase. The fusion protein of claim 3 or 4, wherein the Caspase domain comprises or consists of the amino acid sequence of SEQ m NO: 64, SEQ ID NO: 65, SEQ BD NO: 67 or SEQ m NO: 68; or functionally active variants, particularly fragments thereof. 
Fuzijski protein prema zahtjevu 2, gdje je kaspaza od sisavaca, kaspaza od glodavaca ili humana kaspaza, izabrana iz grupe koja obuhvaća Kaspazu-2, Kaspazu-3, Kaspazu-6, Kaspazu-7, Kaspazu-8, Kaspazu-9, Kaspazu-10, Kaspazu-12, najpoželjnije Kaspazu-8 ili Kaspazu-9; i/ili gdje domena kaspaze obuhvaća ili se sastoji od aminokiselinske sekvence SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 67 ili SEQ ID NO: 68.
wherein the linker consists of 1 to 100 amino acid residues, especially, essentially consisting of neutral amino acids; and /or 
gdje se linker sastoji od 1 do 100 aminokiselinskih ostataka, posebno se u biti sastoji od neutralnih aminokiselina; i/ili
culturing the cell according to claim 9 under conditions conducive to the production of the fusion protein. 
uzgoj kulture stanica prema zahtjevu 9 pod uvjetima koji su pogodni za proizvodnju fuzijskog proteina.
identifying the substance as a ligand, depending on its capability to induce apoptosis of the cell. 
identifikacija supstance kao liganda, ovisno o sposobnosti indukcije apoptoze stanice.
A method for the treatment of diabetes mellitus type 2 comprising administering 
Kombinacija za upotrebu za liječenje dijabetes melitusa tipa 2, naznačena time da navedena kombinacija sadrži
The method of claim 8, wherein treatment with a dose of at least 1.5 g/day metformin alone for three months does not adequately control diabetes mellitus type 2. 
Kombinacija za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačena time da tretman samo sa dozom od najmanje 1.5 g/dan metformina tijekom tri mjeseca ne kontrolira adekvatno dijabetes melitus tipa 2.
The oil-extracted product of indigo naturalis as claimed in Claim 1 or 2, wherein in said process, the oil-extracted product obtained after the refining treatment has a decreased indigo content. 
Uljem ekstrahirani produkt prirodnog indiga u skladu s patentnim zahtjevom 1 ili 2, naznačen time što u navedenom postupku uljem ekstrahirani produkt dobiven nakon rafinacijske obrade ima smanjeni sadržaj indiga.